Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–89 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Adalimumab Placebo Clear all
Completed Phase 4 Interventional Results available

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055
View directory record Official record
Conditions
Rhematoid Arthritis
Interventions
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
60
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Phase 2 Interventional

Precision Depression Adalimumab Trial

NCT07845604
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Adalimumab Biosimilars Injection, Placebo
Drug · Other
Lead sponsor
Daniel Moriarity
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02207231
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
26
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

NCT00918255
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
adalimumab, Placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574
View directory record Official record
Conditions
Type 1 Diabetes, New Onset
Interventions
Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
9 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT06972446
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lutikizumab, Placebo, Ravagalimab, ABBV-8736, ABBV-701, ABBV-848, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
49
States / cities
Peoria, Arizona • Jonesboro, Arkansas • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 4 Interventional Results available

Adalimumab in JIA-associated Uveitis Stopping Trial

NCT03816397
View directory record Official record
Conditions
Uveitis, JIA
Interventions
Adalimumab, Placebo
Biological · Other
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

NCT03259074
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
19
States / cities
Mesa, Arizona • Escondido, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

NCT02332590
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Adalimumab, Placebo (for sarilumab), Placebo (for adalimumab)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Covina, California • Long Beach, California • Whittier, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04988308
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bermekimab, Adalimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 4, 2026, 1:02 AM EDT
Not yet recruiting No phase listed Observational

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

NCT06016517
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Etanercept, Adalimumab, Upadacitinib, Tocilizumab
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03759288
View directory record Official record
Conditions
Crohn's Disease, IBD
Interventions
Brazikumab low dose, Brazikumab high dose, Humira®, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

NCT00077779
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
43
States / cities
La Jolla, California • San Francisco, California • Arvada, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2007 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

Remission in Subjects With Crohn's Disease, Open Label Extension

NCT01070303
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab 40 mg eow or ew
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
43
States / cities
Berkeley, California • Long Beach, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT03823391
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-3373, Placebo for ABBV-3373, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

NCT02065557
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Placebo
Biological
Lead sponsor
AbbVie
Industry
Eligibility
4 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 4, 2026, 1:02 AM EDT